INTRODUCTION
============

All cataract surgeries are subject to the risk of postoperative complications. Persistent inflammation and cystoid macular edema (CME) can cause postoperative vision loss \[[@R1],[@R2],[@R3]\]. Infectious endophthalmitis, whereas rare, is another serious vision-threatening complication \[[@R4],[@R5],[@R6]^▪▪^\]. Prophylactic therapies are used to reduce the risk of postoperative endophthalmitis, inflammation, and CME, and their development is driven by the need to optimize surgical outcomes without unduly burdening the patient.

Topical ophthalmic medications are the standard of care for the prophylaxis of postoperative endophthalmitis. A 2014 survey of members of the American Society of Cataract and Refractive Surgery found that 97% of respondents prescribe postoperative antibiotic drops to reduce the risk of postoperative endophthalmitis \[[@R7]\]. Despite their almost unanimous use, the efficacy of topical ophthalmic antibiotics for endophthalmitis prophylaxis has never been demonstrated in a prospective randomized clinical trial.

Topical ophthalmic corticosteroids and NSAIDs are also available with varying indications for the treatment or prevention of postoperative inflammation and CME. The efficacy of these options has been demonstrated across multiple clinical studies, but safety concerns remain, including the potential for intraocular pressure (IOP) increases with the use of corticosteroid drops.

Despite being the current standard of postoperative cataract care, eye drop regimens are often associated with patient nonadherence. Prescription eye drops can be expensive, and treatment regimens are often complex, sometimes including up to three medications, each requiring different numbers of drops at various intervals throughout the day for up to several weeks \[[@R1],[@R8]\]. A compliance monitoring study found that cataract surgery patients only applied half of the prescribed number of postoperative drops \[[@R9]\]. A separate video-based analysis found that 93% of eye-drop naïve patients used improper technique when applying postoperative drops \[[@R10]\]. Examples of improper techniques include the drop missing the eye, instilling an incorrect number of drops in one dose, and contaminating the bottle tip \[[@R10]\]. The same study also reported that less than half of the patients waited 5 min between instilling different eye-drop medications \[[@R10]\].

Results above suggest the need for a simpler prophylactic therapy, one that reduces or eliminates the patient burden of postoperative eye drops while remaining as well tolerated and effective. Single-use injections that are administered directly into the eye during surgery have been developed to meet this need. An intracameral injection of antibiotics, including cefuroxime, vancomycin, and moxifloxacin, has been shown to be well tolerated and effective at reducing the rate of postoperative endophthalmitis \[[@R11]--[@R13],[@R14]^▪▪^,[@R15]^▪▪^,[@R16],[@R17]\]. In the case of vancomycin, a retrospective analysis of more than 16 000 cases showed that an intracameral injection of 1-mg vancomycin reduced the rate of postoperative endophthalmitis more than 37-fold \[[@R12]\]. Studies have also shown that an intracameral injection of vancomycin or moxifloxacin is well tolerated for the cornea and retina \[[@R18],[@R19],[@R20]\].

Intraocular injections have also been developed to reduce the risk of postoperative inflammation, and clinical studies have shown that an intracameral injection of corticosteroids such as dexamethasone \[[@R21]\] or triamcinolone \[[@R22],[@R23]\] can safely prevent acute or persistent postoperative inflammation without significantly increased IOP.

One concern with intracameral delivery is the ability of a therapeutic agent to access the posterior segment. Studies in rabbit eyes have shown that agents administered by intravitreal injection achieve higher intraocular concentrations, persist longer (up to 3 months) \[[@R24]\], and infiltrate most ocular tissues, including the retina and choroid, when compared with agents that are administered by intracameral injection \[[@R25],[@R26]\].

Clinical studies support the use of intracameral corticosteroids for the prophylaxis of inflammation and CME after cataract surgery \[[@R27],[@R28]\]. Control of inflammation was similar to topical medications, whereas clinically significant IOP increases were rare.

A regulated, compounded, preservative-free formulation of triamcinolone acetonide 15 mg/ml, moxifloxacin hydrochloride 1 mg/ml, and vancomycin 10 mg/ml \[triamcinolone--moxifloxacin--vancomycin (TMV), Imprimis Pharmaceuticals, Inc., San Diego, California, USA\] is available for intravitreal administration during cataract surgery for the prophylaxis of postoperative endophthalmitis and inflammation. The design of TMV as a single-use intraoperative prophylactic is thought to decrease both patient and surgeon burden by alleviating the need for complicated postoperative eye-drop regimens. The use of TMV for the prophylaxis of postoperative infection, inflammation, and CME has been evaluated in recently presented clinical experience reports \[[@R29],[@R30]^▪▪^\].

The retrospective chart review reported here was conducted to evaluate the use of intravitreal TMV as an alternative to topical ophthalmic therapies for the prophylaxis of postoperative infection, inflammation, and CME in a large patient cohort. 
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METHODS
=======

Study and patients
------------------

The study was a retrospective analysis of the medical records of 922 patients (1541 eyes) who had cataract surgery with an intravitreal injection of TMV from November 2013 to December 2014. The analysis included surgical cases performed at a single-specialty ambulatory center (SurgiCenter of Vineland, Vineland, New Jersey, USA). Informed consent was obtained from all participants. Data extraction and analysis was HIPAA compliant. The study protocol was approved by the Wills Eye Hospital Institutional Review Board (Philadelphia, Pennsylvania, USA).

Prospective cases for inclusion in the review had cataract surgery with implantation of an intraocular lens (IOL) and at least one intravitreal injection of TMV. The following criteria were used to exclude cases from the analysis: use of topical ophthalmic antibiotics, corticosteroids, or NSAIDs up to 1-week before the scheduled day of surgery; known allergy or hypersensitivity to any of the components of the compounded TMV formulation; history of corticosteroid-responsive glaucoma; history of uncontrolled IOP; and concomitant advanced glaucoma with risk of optic nerve damage in the case of elevated IOP.

Preoperative evaluation, surgical procedure, and postoperative evaluations
--------------------------------------------------------------------------

All cases were evaluated preoperatively, on the day of surgery, and at three postoperative follow-up visits (Days 1, 14--21, and 90) based on anticipated timing of potential postoperative complications, including inflammation and CME. Two surgeons used identical protocols to perform preoperative and postoperative evaluations. The preoperative evaluation included slit lamp ophthalmoscopy, dilated fundoscopy, uncorrected visual acuity (UCVA), and best corrected visual acuity (BCVA) measured on a standard Snellen chart at 20 ft and IOP measured with a Goldmann applanation tonometer (AT 900, Haag-Streit Diagnostics, Koeniz, Switzerland). All patients were advised of the possible presence of floaters after TMV injection.

Standard surgical protocols were used in all cases. A slurry of 2% lidocaine gel, phenylephrine hydrochloride 2.5% (Paragon BioTeck, Inc., Portland, Oregon, USA), and Cyclogyl 2% (cyclopentolate hydrochloride, Alcon Laboratories, Inc., Fort Worth, Texas, USA) was applied to the inferior cul-de-sac of the operative eye 10 min before surgery. A 10% povidone--iodine solution was applied to the skin around the operative site, and a 5% solution was applied to the conjunctival sac 5 min before surgery. Cataract surgery was performed by a standard clear corneal phacoemulsification technique using the INFINITI Vision System (Alcon Laboratories, Inc.).

A transzonular injection of 0.2 ml TMV (3.0 mg triamcinolone acetonide, 0.2 mg moxifloxacin, and 2.0 mg vancomycin) was administered into the anterior vitreous after IOL implantation but before viscoelastic removal. Viscoelastic was used to expand the ciliary sulcus prior to injection. The TMV formulation was slowly injected through the zonules via the ciliary sulcus inferonasally with a 30-ga Rycroft cannula. Intravitreal TMV placement was visually confirmed by the appearance of a white plume in the vitreous (Fig. [1](#F1){ref-type="fig"}). A second or third TMV injection was permitted if the surgeon deemed the first (or second) injection to be inadequate. Viscoelastic was removed immediately after administration and confirmation of the TMV injection.

![Surgical view of a transzonular intravitreal injection of a compounded triamcinolone--moxifloxacin--vancomycin formulation. A transzonular intravitreal injection of 0.2 ml triamcinolone--moxifloxacin--vancomycin was administered into the anterior vitreous after implantation of a multifocal toric intraocular lens. The triamcinolone--moxifloxacin--vancomycin formulation was injected through the zonules via the ciliary sulcus inferonasally with a 30-ga Rycroft cannula. Intravitreal triamcinolone--moxifloxacin--vancomycin placement was visually confirmed by the appearance of a white plume in the vitreous.](cooph-28-73-g002){#F1}

One drop each of PRED FORTE (prednisolone acetate) 1% (Allergan, Inc., Irvine, California, USA), a fluoroquinolone, and a topical ophthalmic antihypertensive were instilled into the operative eye immediately after surgery.

Postoperative evaluations included the following measurements and/or assessments: UCVA, BCVA, and IOP at all follow-up visits; presence of endophthalmitis at any follow-up visit; breakthrough inflammation at Days 14--21 or 90, defined as ocular pain, photophobia, ciliary flush, or other signs and symptoms that required supplemental anti-inflammatory medication; and visually significant CME at Days 14--21 and 90, defined as decreased BCVA with optical coherence tomography (OCT)-confirmed retinal thickening.

Assessments and statistical analyses
------------------------------------

Analysis of the data records included a summary of patient demographics and a review of the surgical results. Postoperative analyses included the changes in BCVA and UCVA over time; UCVA and BCVA were converted into log MAR for aggregate analysis, with aggregate data converted back to Snellen acuity for reporting purposes. The rates of CME, breakthrough inflammation and endophthalmitis were also analyzed, as well as IOP pressure changes over time and any supplemental postoperative medication use.

A two-tailed *t*-test was used to determine statistically significant differences between mean values of parametric variables, with a repeated measures analysis of variance (ANOVA) used to compare parametric data over time. The chi-squared test of independence was used to determine statistically significant differences between proportions. Statistical significance was defined as a *P*-value less than 0.05. Statistical analyses were performed using the STATISTICA data analysis software system, version 13 (StatSoft, Inc., Tulsa, Oklahoma, USA).

RESULTS
=======

Patient characteristics
-----------------------

The chart review included 1541 eyes of 922 patients; case demographics and preoperative ocular characteristics are reported in Table [1](#T1){ref-type="table"}. Nearly one-third of cases (*n* = 504/1541) had a concomitant medical or ocular condition, the most common being diabetes (29.1%, *n* = 448/1541) followed by glaucoma (4.4%, *n* = 68/1541).

Surgical experience
-------------------

Most cases (96.3%, *n* = 1484/1541) received a single injection of TMV during surgery. Fifty-six cases (3.6%, *n* = 56/1541) required a second TMV injection, and one case (0.1%, *n* = 1/1541) required a third injection. No case required more than three injections.

There were no major intraoperative complications. The unplanned vitrectomy rate was 0.45% (*n* = 7/1541). All vitrectomy cases received an injection of TMV without complication; in fact, the TMV served to stain the vitreous and greatly assisted in vitreous cleanup. There were no cases of zonular disruption, hyphema, or vitreous hemorrhage. There were no cases of iatrogenic retinal tear or detachment. There were isolated cases of iris prolapse in chambers that had been overfilled with viscoelastic. There were four cases of ciliary body hemorrhage. All cases were self-limiting or readily stanched with compounded lidocaine hydrochloride 1%/phenylephrine hydrochloride 1.5% (JCB Laboratories, Wichita, Kansas, USA), which was used for intracameral dilation.

Postoperative results
---------------------

Visual acuity data are summarized in Table [2](#T2){ref-type="table"}, with the mean log MAR UCVA and BCVA at each visit, along with the Snellen equivalent of that mean value. There was a statistically significant improvement in the postoperative BCVA and UCVA, as expected. A repeated measures ANOVA showed that the BCVA was statistically significantly different between postoperative visits (*n* = 158, *P* = 0.19), but the difference was clinically insignificant (less than half a log MAR line). A repeated measures ANOVA also showed that UCVA was statistically significantly different between visits (*n* = 871, *P* \< 0.01), improving by about 1 log MAR line from Days 1 to 14--21 and another log MAR line between Days 14--21 and 90.

Table [3](#T3){ref-type="table"} summarizes findings related to breakthrough inflammation at Days 14--21. At Day 90, there were 26 cases of inflammation: 14 new cases and 12 cases that were persistent from Days 14 to 21. All cases with breakthrough inflammation at Days 14--21 received supplemental medication. The rate of breakthrough inflammation at Days 14--21 was significantly higher among surgeries performed during the first 7 months of the analysis period (11.2%, *n* = 74/661) compared with those performed in the second 7 months (7.8%, *n* = 58/768, *P* = 0.02). The rate of inflammation in cases with concomitant diabetes was not significantly different from cases without (chi-squared test, *P* = 0.97). However, there were significantly more cases of breakthrough inflammation in patients diagnosed with glaucoma (chi-squared test, *P* = 0.02). Using ethnicity and race as a general surrogate for iris color, the rate of breakthrough inflammation was compared between white and nonwhite patients; there was no statistically significant difference observed (chi-squared test, *P* = 0.15).

Table [4](#T4){ref-type="table"} summarizes the findings related to visually significant postoperative CME at Days 14--21 or 90 was 2.0% (*n* = 28/1429). Most cases (79%, *n* = 22/28) received supplemental medication (Table [3](#T3){ref-type="table"}). The rate of CME cases with concomitant diabetes was not statistically significantly different from the rate in patients without diabetes (chi-squared test, *P* = 0.14), though the rate in eyes with a preoperative epiretinal membrane was statistically significantly higher (chi-squared test, *P* \< 0.01). One-third (10/28) of the cases of CME also had breakthrough inflammation, a significantly higher rate than for eyes without CME (chi-squared, *P* \< 0.01).

Mean IOP was lower than preoperative at all postoperative visits (Table [5](#T5){ref-type="table"}). A repeated measures ANOVA showed the differences were statistically significantly different, but the mean differences were not clinically significant; all means were within 2 mmHg of each other. The rate of clinically significant postoperative IOP increase was low: 0.9% (*n* = 13/1425) of cases had an at least 10 mmHg increase at Days 14--21 or 90. Four of these cases had IOP at least 30 mmHg. One case received IOP-lowering medication. The proportion of cases with increased IOP was significantly higher in the eyes with concomitant glaucoma compared with those without glaucoma (4/68 vs 9/1361, chi-squared test, *P* \< 0.01). Among cases with clinically significant IOP increase at Days 14--21, most were resolved at Day 90 (90.9%, *n* = 10/11, with IOP ≤ 21 mmHg). None of the resolved cases received IOP-lowering medications. The unresolved case (IOP 31 mmHg at Day 90) had optic neuropathy prior to surgery. No cases required surgical intervention to resolve increased IOP.

There were no cases of postoperative endophthalmitis. There were no other postoperative complications, including toxic anterior segment syndrome (TASS) or hemorrhagic occlusive retinal vasculitis (HORV). There were no cases of IOL instability, decentration, or migration. Though superiorly located (due to the inferior injection location) peripheral floaters and blurred vision were perceived among many cases in the immediate postoperative period; this did not appear to affect postoperative visual outcomes including visual acuity at Day 1. There were no reports of persistent floaters among cases throughout the remaining postoperative period. There were no cases of postoperative retinal tear or detachment through a year of follow-up.

DISCUSSION
==========

The current retrospective chart review of 1541 cataract surgery cases evaluated the use of a transzonular intravitreal injection for the prophylaxis of postoperative infection, inflammation, and CME. The absence of postoperative endophthalmitis in this case series analysis supports the use of intravitreal TMV as a prophylactic antibiotic, but the size of the data set limits any definitive conclusion in this regard. Modern prophylactic methods have achieved postoperative endophthalmitis rates below 0.01% according to some studies \[[@R31]\], which means more than 10 000 eyes often need to be evaluated before an endophthalmitis-positive case is detected.

The rate of postoperative breakthrough inflammation after TMV (9.2% at Days 14--21) was similar to what has been reported for topical ophthalmic corticosteroids, such as difluprednate 0.05% (10.1% at Day 28) \[[@R32]\] and dexamethasone 1 mg/ml (given as TobraDex, Alcon Laboratories, Inc., 13% breakthrough inflammation at Day 21) \[[@R33]\]. The previous work has identified factors that are associated with increased rates of postoperative inflammation, including dark iris color and history of inflammatory conditions such as uveitis \[[@R34],[@R35]\]. We did not observe a difference in breakthrough inflammation between white and nonwhite patients, though categorization by ethnicity and race is an admittedly imprecise surrogate for iris color.

The rate of visually significant postoperative CME after TMV was similar to rates previously reported with topical ophthalmic corticosteroids, including prednisolone 1% four times a day (QID) (2.1% with at least 1-month follow-up) \[[@R36]\]. Previous studies have suggested a higher rate of CME in diabetic patients or patients with diabetic retinopathy \[[@R37]\]; our results did not show this.

The rate of clinically significant IOP increase after TMV in this data set was low, and similar to what has been reported with topical ophthalmic corticosteroids, such as difluprednate 0.05% (2.8% with IOP ≥ 21 mmHg and IOP change ≥10 mmHg after) \[[@R38]\] and prednisolone 1% (2.4% with ≥10 mmHg change) \[[@R39]\]. Most cases resolved by Day 90, and those that resolved did so without IOP-lowering medication. Importantly, no cases required surgical intervention to achieve resolution of postoperative increased IOP. These findings suggest that intravitreal placement of the triamcinolone in TMV does not have a significant impact on postoperative IOP in most cases. This is supported by a previous study that demonstrated the IOP safety of low-dose (up to 3 mg) triamcinolone intravitreal injections \[[@R27]\].

There were no other postoperative complications, including TASS or HORV, which is a rare but serious complication that was recently identified in a small number of patients after uneventful cataract surgery that included a prophylactic intracameral injection of vancomycin \[[@R40]\].

There are questions about how the white triamcinolone plume in the vitreous affects patient vision in the early postoperative period after cataract surgery with TMV. As part of managing expectations after surgery, all patients were educated about the possibility of floaters and visual obscuration in the early postoperative period. Floaters were reported by many patients, but they did not persist.

We believe this is the first large-scale case series to evaluate the use of an intravitreal TMV injection for the prophylaxis of postoperative infection, inflammation, and CME associated with cataract surgery. The results of this retrospective chart review show that intravitreal TMV eliminated the need for supplemental postoperative medication, either topical ophthalmic medications or intraocular injections, in more than 91% of cases. There were no major intraoperative or postoperative complications observed, the rate of clinically significant IOP was 0.9%, and no cases required surgical intervention to resolve increased IOP. This suggests that TMV is a viable alternative to topical medications for postcataract prophylaxis. The transzonular intravitreal injection of TMV during cataract surgery has significant potential to ease the burden of postoperative care for patients and surgical practices.

CONCLUSION
==========

There are many theoretical benefits of a single-use intraoperative prophylactic such as TMV: cost savings for the patient, who no longer needs to purchase postoperative eye drops; cost savings for the surgical practice, which no longer needs to spend time and human resources on explaining complicated eye drop regimens; fewer complications associated with reduced ability to self-administer postoperative eye drops, especially in cases with elderly patients; and potential improvements in surgical outcomes that are no longer dependent on patient adherence to a postoperative treatment regimen.
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###### 

Case demographics and preoperative ocular characteristics

  Characteristic                                                        
  --------------------------------------------------------------------- -------------
  Number of eyes (cases) (*n*)                                          1541
  Sex \[number of patients (%)\]                                        
   Female                                                               554 (60.1)
   Male                                                                 368 (39.9)
  Age (years)                                                           
   Mean (SD)                                                            70.4 (9.8)
   Median (range)                                                       71 (18--98)
  Ethnicity, number of patients (%)[^a^](#TF1-1){ref-type="table-fn"}   
   Hispanic, Latino, or Spanish                                         114 (12.4)
   Not Hispanic, Latino, or Spanish                                     807 (87.6)
  Race \[number of patients (%)\][^b^](#TF1-2){ref-type="table-fn"}     
   Asian                                                                16 (1.7)
   Black or African-American                                            105 (11.4)
   White                                                                686 (74.5)
  Concomitant conditions \[number of cases (%)\]                        
   Diabetes                                                             448 (29.1)
   Glaucoma                                                             68 (4.4)
   Epiretinal membrane                                                  11 (0.7)
   Diabetes + glaucoma                                                  22 (1.4)
   Diabetes + epiretinal membrane                                       1 (0.1)
  IOP (mmHg)                                                            
   Number of cases (*n*)                                                1517
   Mean (SD)                                                            15.4 (3.5)
   Range                                                                5.7--30
  Cataract density \[number of cases (%)\]                              
   Number of cases (*n*)                                                1534
   1 and 1+                                                             158 (10.3)
   2 and 2+                                                             653 (42.6)
   3 and 3+                                                             670 (43.7)
   4 and 4+                                                             53 (3.4)

IOP, intraocular pressure.

^a^Ethnicity was not available for one patient (*n* = 921).

^b^Race was only recorded for patients who were not Hispanic, Latino, or Spanish (*n* = 807).

###### 

Mean visual acuity at all time points

  Mean visual acuity                              
  ---------------------------- ------ ----------- -------------
  UCVA                                            
   Before surgery              919    20/100--1   0.72 (0.68)
   Day 1 after surgery         1511   20/50--2    0.44 (0.46)
   Days 14--21 after surgery   1325   20/40--2    0.33 (0.34)
   Day 90 after surgery        993    20/40+1     0.28 (0.34)
  BCVA                                            
   Before surgery              878    20/60+2     0.46 (0.46)
   Day 1 after surgery         381    20/25--2    0.14 (0.19)
   Days 14--21 after surgery   758    20/25--3    0.16 (0.25)
   Day 90 after surgery        720    20/25--2    0.15 (0.22)

*Note:* Visual acuity data that were entered by surgeon as count fingers, hand motion, or light perception were quantified as log MAR 2.3 (Snellen 1/200), 2.6 (0.5/200), or 3.9 (0.025/200) for the purpose of analysis. BCVA, best-corrected visual acuity; UCVA, uncorrected visual acuity.

###### 

Summary of breakthrough inflammation after surgery with an intravitreal injection of triamcinolone--moxifloxacin--vancomycin

  Breakthrough inflammation (*n* = 1429[^a^](#TF3-1){ref-type="table-fn"})   
  -------------------------------------------------------------------------- -----------------------------------------
  Cases with breakthrough inflammation at Days 14--21 \[*n* (%)\]            132 (9.2)
  Concomitant conditions (cases with inflammation/total eyes)                
   Diabetes                                                                  41/448
   Glaucoma                                                                  11/57[^b^](#TF3-2){ref-type="table-fn"}
  Ethnicity and race (cases with inflammation/total eyes)                    
   Nonwhite                                                                  40/347
  Medications prescribed                                                     
   Total                                                                     147[^c^](#TF3-3){ref-type="table-fn"}
   Corticosteroid                                                            72
   Nonsteroidal anti-inflammatory drug                                       75

^a^A total of 112 cases did not return for a follow-up at Days 14--21.

^b^Statistically significantly different from the proportion of cases without the corresponding concomitant condition in the overall case set (*n* = 1429), chi-squared test.

^c^Some cases received more than one medication, so the number of medications differs from the number of cases that received medication.

###### 

Rates of visually significant cystoid macular edema after surgery with an intravitreal injection of triamcinolone--moxifloxacin--vancomycin

  Visually significant postoperative CME[^d^](#TF4-4){ref-type="table-fn"} (*n* = 1429[^a^](#TF4-1){ref-type="table-fn"})   
  ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  Cases with visually significant CME at Days 14--21 or 90 \[*n* (%)\]                                                      28 (2.0)
  Cases that received medication for CME at Days 14--21 or 90                                                               22/28 (78.6)
  Concomitant conditions (cases with CME/total eyes)                                                                        
   Diabetes                                                                                                                 12/448
   Epiretinal membrane                                                                                                      2/11[^b^](#TF4-2){ref-type="table-fn"}
  Medications prescribed                                                                                                    
   Total                                                                                                                    32[^c^](#TF4-3){ref-type="table-fn"}
   Corticosteroid                                                                                                           12
   Nonsteroidal anti-inflammatory                                                                                           20

CME, cystoid macular edema.

^a^A total of 112 cases did not return for follow-up at Days 14--21.

^b^Statistically significantly different from the proportion of cases without the corresponding concomitant condition in the overall case set (*n* = 1429), chi-squared test.

^c^Some cases received more than one medication, so the number of medications differs from the number of cases that received medication.

^d^Only includes cases of visually significant CME that emerged after cataract surgery. Excludes cases of CME that were present before surgery or at preoperative evaluation.

###### 

Mean intraocular pressure after surgery with an intravitreal injection of triamcinolone--moxifloxacin--vancomycin

  Mean IOP                           
  --------------------------- ------ ------------
  Before surgery              1517   15.4 (3.6)
  Day 1 after surgery         1514   14.3 (4.3)
  Days 14--21 after surgery   1301   14.2 (3.7)
  Day 90 after surgery        1067   13.7 (3.3)

IOP, intraocular pressure.

^a^*P* \< 0.0001 when compared with mean preoperative IOP. Analysis of statistical significance performed using two-tailed *t* test.
